MedTrace Logo

Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers

NCT01987011 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2015-07-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.

Conditions

Interventions

BIOLOGICAL

MG1109

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Korean Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Woo Joo Kim, MD, Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2013-10-31
Completion
2014-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987011 on ClinicalTrials.gov